Clinical trial · Interventional
Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection
Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Brain Meningioma Resections: Study Protocol of a Randomised Controlled Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Intra-operative blood loss of huge meningioma resection patients on average was over 1000ml. Intra-operative massive hemorrhage was associated with longer hospital of stay, higher expense, and higher mortality. Previous studies indicated intra-operative tranexamic acid infusion would decrease blood loss for cardiac, trauma and obstetric procedures. However, limited researches focusing on the effect of tranexamic acid in neurosurgery population, with heterogenous pathologies. The purpose of this study was to investigate the effect of tranexamic acid on intra-operative blood loss in patients undergoing huge meningioma resection.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Intraoperative Blood Loss | — | UNRESOLVED | — |
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
| Tranexamic Acid | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Continous infusion | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
| Single infusion | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Continous infusion group
- description
- Infusion with 20mg/kg tranexamic acid and 5mg/kg/h tranexamic acid.
- interventionNames
- Drug: Continous infusion
- type
- ACTIVE_COMPARATOR
- label
- Single infusion group
- description
- Infusion with 20mg/kg tranexamic acid and same volume 0.9% saline.
- interventionNames
- Drug: Single infusion
- type
- PLACEBO_COMPARATOR
- label
- Placebo group
- description
- Infusion with same volume of 0.9% saline.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing elective supratentorial meningioma resection with estimated tumor diameter \>5cm on brain image. * Age between 18-65 years. * American Society of Anaesthesiologist (ASA) physical status Ⅰ to Ⅲ * Obtain written informed consent. Exclusion Criteria: * Allergic to tranexamic acid. * History of thrombotic disease. * History of chronic kidney disease * Receiving other anticoagulation or antiplatelet treatment. * Refuse to provide written informed consent
References
Publications (2)
- DERIVEDLi S, Liu M, Zhang L, Ren Y, Wu Y, Yin X, Zeng M, Zhou D, Sessler DI, Peng Y. Effect of tranexamic acid on blood loss in patients undergoing resection of large meningioma: a randomized clinical trial. Sci Rep. 2026 May 11;16(1):21458. doi: 10.1038/s41598-026-52276-2. PMID 42115323
- DERIVEDYu H, Liu M, Zhang X, Ma T, Yang J, Wu Y, Wang J, Li M, Wang J, Zeng M, Zhang L, Jin H, Liu X, Li S, Peng Y. The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. PLoS One. 2023 Aug 31;18(8):e0290725. doi: 10.1371/journal.pone.0290725. eCollection 2023. PMID 37651373